{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:29:02Z","timestamp":1772915342228,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900130"],"award-info":[{"award-number":["81900130"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970136"],"award-info":[{"award-number":["81970136"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970142"],"award-info":[{"award-number":["81970142"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000132"],"award-info":[{"award-number":["82000132"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8217011130"],"award-info":[{"award-number":["8217011130"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8210010924"],"award-info":[{"award-number":["8210010924"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00277-023-05106-8","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T14:03:47Z","timestamp":1675433027000},"page":"777-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular genetics and management of world health organization defined atypical\u00a0chronic\u00a0myeloid\u00a0leukemia"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-3211","authenticated-orcid":false,"given":"Yingxin","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"5106_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc.2017.40","volume":"17","author":"MWN Deininger","year":"2017","unstructured":"Deininger MWN, Tyner JW, Solary E (2017) Turning the tide in myelodysplastic\/myeloproliferative neoplasms. Nat Rev Cancer 17:425\u2013440. https:\/\/doi.org\/10.1038\/nrc.2017.40","journal-title":"Nat Rev Cancer"},{"key":"5106_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/cancers13092120","volume":"13","author":"L Palomo","year":"2021","unstructured":"Palomo L, Acha P, Sol\u00e9 F (2021) Genetic aspects of myelodysplastic\/myeloproliferative neoplasms. Cancers 13:2120. https:\/\/doi.org\/10.3390\/cancers13092120","journal-title":"Cancers"},{"key":"5106_CR3","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1002\/cncr.33622","volume":"127","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K et al (2021) Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127:3113\u20133124. https:\/\/doi.org\/10.1002\/cncr.33622","journal-title":"Cancer"},{"key":"5106_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ajh.24722","volume":"92","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Barraco D, Lasho TL et al (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542\u2013548. https:\/\/doi.org\/10.1002\/ajh.24722","journal-title":"Am J Hematol"},{"key":"5106_CR5","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","volume":"122","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Maxson JE, George TI, Tyner JW (2013) The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 122:1707\u20131711. https:\/\/doi.org\/10.1182\/blood-2013-05-500959","journal-title":"Blood"},{"key":"5106_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R, Valletta S, Winkelmann N et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18\u201324. https:\/\/doi.org\/10.1038\/ng.2495","journal-title":"Nat Genet"},{"key":"5106_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"5106_CR8","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R et al (2015) An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood 125:1857\u20131865. https:\/\/doi.org\/10.1182\/blood-2014-10-607341","journal-title":"Blood"},{"key":"5106_CR9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ng.2696","volume":"45","author":"H Makishima","year":"2013","unstructured":"Makishima H, Yoshida K, Nguyen N et al (2013) Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 45:942\u2013946. https:\/\/doi.org\/10.1038\/ng.2696","journal-title":"Nat Genet"},{"key":"5106_CR10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/leu.2013.145","volume":"27","author":"F Thol","year":"2013","unstructured":"Thol F, Suchanek KJ, Koenecke C et al (2013) SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 27:2072\u20132075. https:\/\/doi.org\/10.1038\/leu.2013.145","journal-title":"Leukemia"},{"key":"5106_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.2019000611","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wilmot B, Bottomly D et al (2019) Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134:867\u2013879. https:\/\/doi.org\/10.1182\/blood.2019000611","journal-title":"Blood"},{"key":"5106_CR12","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd A, Levine RL, Ruppert AS et al (2020) Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med 26:1852\u20131858. https:\/\/doi.org\/10.1038\/s41591-020-1089-8","journal-title":"Nat Med"},{"key":"5106_CR13","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.3390\/ijms21186862","volume":"21","author":"E Cris\u00e0","year":"2020","unstructured":"Cris\u00e0 E, Nicolosi M, Ferri V et al (2020) Atypical chronic myeloid leukemia: where are we now? Int J Mol Sci 21:6862. https:\/\/doi.org\/10.3390\/ijms21186862","journal-title":"Int J Mol Sci"},{"key":"5106_CR14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S et al (2020) Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasmsomo. Blood 136:1851\u20131862. https:\/\/doi.org\/10.1182\/blood.2019004229","journal-title":"Blood"},{"key":"5106_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:352\u2013372. https:\/\/doi.org\/10.1002\/ajh.26455","journal-title":"Am J Hematol"},{"key":"5106_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ajh.25950","volume":"95","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, Chien KS, Montalban-Bravo G (2020) Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol 95:1399\u20131420. https:\/\/doi.org\/10.1002\/ajh.25950","journal-title":"Am J Hematol"},{"key":"5106_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96:145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"key":"5106_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"5106_CR19","doi-asserted-by":"publisher","unstructured":"Mart\u00edn-Izquierdo M, Ab\u00e1igar M, Hern\u00e1ndez-S\u00e1nchez JM, et al (2020) Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. Haematologica 106. https:\/\/doi.org\/10.3324\/haematol.2020.248807","DOI":"10.3324\/haematol.2020.248807"},{"key":"5106_CR20","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","volume":"12","author":"RM Carr","year":"2021","unstructured":"Carr RM, Vorobyev D, Lasho T et al (2021) RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun 12:2901. https:\/\/doi.org\/10.1038\/s41467-021-23186-w","journal-title":"Nat Commun"},{"key":"5106_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E et al (2016) Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128:1408\u20131417. https:\/\/doi.org\/10.1182\/blood-2016-05-714030","journal-title":"Blood"},{"key":"5106_CR22","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A (2016) Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J 6:e393\u2013e393. https:\/\/doi.org\/10.1038\/bcj.2016.5","journal-title":"Blood Cancer J"},{"key":"5106_CR23","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1038\/s41375-020-0752-x","volume":"34","author":"EC DiFilippo","year":"2020","unstructured":"DiFilippo EC, Coltro G, Carr RM et al (2020) Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS\/MPN overlap neoplasms. Leukemia 34:2519\u20132524. https:\/\/doi.org\/10.1038\/s41375-020-0752-x","journal-title":"Leukemia"},{"key":"5106_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M et al (2022) CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 139:87\u2013103. https:\/\/doi.org\/10.1182\/blood.2020009680","journal-title":"Blood"},{"key":"5106_CR25","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM et al (2020) Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 4:2866\u20132870. https:\/\/doi.org\/10.1182\/bloodadvances.2020001482","journal-title":"Blood Adv"},{"key":"5106_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood-2019-124994","volume":"134","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, Pollyea DA, Garcia JS et al (2019) A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood 134:565\u2013565. https:\/\/doi.org\/10.1182\/blood-2019-124994","journal-title":"Blood"},{"key":"5106_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2019-124437","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei AH, Garcia JS, Borate U et al (2019) A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome. Blood 134:568\u2013568. https:\/\/doi.org\/10.1182\/blood-2019-124437","journal-title":"Blood"},{"key":"5106_CR28","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1182\/blood-2021-153170","volume":"138","author":"SPP Desikan","year":"2021","unstructured":"Desikan SPP, Montalban-Bravo G, Ohanian M et al (2021) A phase I study of the combination of venetoclax and azacitidine in relapse\/refractory higher risk myelodysplastic syndrome (MDS). Blood 138:3704\u20133704. https:\/\/doi.org\/10.1182\/blood-2021-153170","journal-title":"Blood"},{"key":"5106_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2021-153086","volume":"138","author":"A Bazinet","year":"2021","unstructured":"Bazinet A, Jabbour EJ, Kantarjian H et al (2021) A phase I\/II study of venetoclax in combination with 5-azacytidine in treatment-na\u00efve and relapsed\/refractory high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). Blood 138:535\u2013535. https:\/\/doi.org\/10.1182\/blood-2021-153086","journal-title":"Blood"},{"key":"5106_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.19.00895","volume":"38","author":"KHT Dao","year":"2020","unstructured":"Dao KHT, Gotlib J, Deininger MMN et al (2020) Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol 38:1006\u20131018. https:\/\/doi.org\/10.1200\/JCO.19.00895","journal-title":"J Clin Oncol"},{"key":"5106_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G et al (2018) A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol 93:277\u2013285. https:\/\/doi.org\/10.1002\/ajh.24972","journal-title":"Am J Hematol"},{"key":"5106_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","volume":"129","author":"J Gotlib","year":"2017","unstructured":"Gotlib J (2017) How I treat atypical chronic myeloid leukemia. Blood 129:838\u2013845. https:\/\/doi.org\/10.1182\/blood-2016-08-693630","journal-title":"Blood"},{"key":"5106_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11899-016-0350-1","volume":"11","author":"C Talati","year":"2016","unstructured":"Talati C, Padron E (2016) An exercise in extrapolation: clinical management of atypical CML, MDS\/MPN-unclassifiable, and MDS\/MPN-RS-T. Curr Hematol Malig Rep 11:425\u2013433. https:\/\/doi.org\/10.1007\/s11899-016-0350-1","journal-title":"Curr Hematol Malig Rep"},{"key":"5106_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.14619","volume":"177","author":"F Onida","year":"2017","unstructured":"Onida F, de Wreede LC, van Biezen A et al (2017) Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol 177:759\u2013765. https:\/\/doi.org\/10.1111\/bjh.14619","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05106-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05106-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05106-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T21:13:57Z","timestamp":1678396437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05106-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5106"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05106-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"23 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}